Autoimmunity And Immune Deficiency After Spinal Cord Injury: Association With Rehabilitation Outcomes

NCT04211636 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2023-02-08

No results posted yet for this study

Summary

The SCIentinel-prolong study systematically analyzes humoral autoantibody responses and thier interaction with post-spinal cord injury (SCI) immune-deficiency and infections as well as their association with the clinical course of rehabilitation. Therefore, molecular and immunological tests in blood and cerebrospinal fluid specimen are combined with clinical outcomes ranging from neurological function, neuropathic pain and spasticity to walking tests and measures of independence in daily living within the first year after SCI. Including a control group with participants suffering from vertebral fractures without SCI allows to differentiate between neurological and general injury and treatment effects.

Conditions

  • Spinal Cord Trauma

Sponsors & Collaborators

  • Foundation Wings For Life

    collaborator OTHER
  • University Hospital Tuebingen

    collaborator OTHER
  • Unfallkrankenhaus Berlin

    collaborator OTHER
  • Balgrist University Hospital

    collaborator OTHER
  • I.R.C.C.S. Fondazione Santa Lucia

    collaborator OTHER
  • University of Zurich

    collaborator OTHER
  • Medical University of Vienna

    collaborator OTHER
  • Ruhr University of Bochum

    collaborator OTHER
  • Swiss Federal Institute of Technology

    collaborator OTHER
  • King's College London

    collaborator OTHER
  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER
  • Ohio State University

    collaborator OTHER
  • Marcel Kopp, MD

    lead OTHER

Principal Investigators

  • Jan M Schwab, MD, PhD · Ohio State University

  • Marcel A Kopp, MD · Charite University, Berlin, Germany

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2025-10-31
Completion
2026-04-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04211636 on ClinicalTrials.gov